Jounce Therapeutics is a technology company.
Jounce Therapeutics has raised $47.0M across 1 funding round.
Key people at Jounce Therapeutics.
Jounce Therapeutics has raised $47.0M in total across 1 funding round.
Key people at Jounce Therapeutics.
Jounce Therapeutics has raised $47.0M in total across 1 funding round.
Jounce Therapeutics's investors include Deerfield Management.
Jounce Therapeutics is a clinical-stage biotechnology company focused on developing cancer immunotherapies that harness the immune system to attack tumors, using a biomarker-driven Translational Science Platform to match therapies to patients.[1][2][3] It targets solid tumors resistant or sensitive to PD-(L)1 inhibitors, with key programs like JTX-8064 (LILRB2/ILT4 antagonist reprogramming tumor-associated macrophages) in Phase 2 trials, vopratelimab (ICOS agonist), and pimivalimab (PD-1 inhibitor).[2][6] The company serves cancer patients by addressing unmet needs in immunotherapy, emphasizing novel approaches for long-lasting benefits, though it underwent a 57% workforce reduction in 2023 to seek partnerships for advancing programs.[2]
Jounce Therapeutics was founded in 2013 by Third Rock Ventures with a $47 million Series A financing, launching from groundbreaking immuno-oncology research at Dana-Farber Cancer Institute and Harvard Medical School.[1][3][4][5] Key founders include immuno-oncology experts Richard Murray, Ph.D. (President and CEO), Gordon Freeman, Ph.D., Glenn Dranoff, M.D., and scientific advisors like James P. Allison, Ph.D., Thomas F. Gajewski, M.D., Ph.D., and others.[5] Early traction came from its focus on first-in-class immunotherapies; in 2016, it secured a $225 million upfront collaboration with Celgene (plus $36.1 million equity) for co-developing biologics, followed by a 2020 exclusive license deal with Gilead for vopratelimab.[1][6]
Jounce rides the immuno-oncology wave, leveraging advances in understanding tumor microenvironments and immune checkpoints post-PD-1 breakthroughs, timing its 2013 launch with rising immunotherapy momentum.[1][3][4] Market forces like demand for personalized, biomarker-guided therapies favor its platform amid challenges in resistance to existing treatments.[2][3] It influences the ecosystem through partnerships (Celgene, Gilead) that validate and scale assets, contributing to a shift toward macrophage reprogramming and combination regimens in solid tumor oncology.[1][2][6]
Jounce's path forward hinges on business development for JTX-8064 and vopratelimab post-2023 restructuring, potentially via acquisitions or licenses to fund Phase 2 expansion in solid tumors.[2] Trends like AI-enhanced biomarkers and next-gen combinations will shape its trajectory, with its platform poised for revival if partnered effectively. As a pioneer in tumor-immune modulation, Jounce could evolve from standalone developer to key asset in big pharma's oncology portfolios, amplifying its mission to transform cancer care.[1][2][3]
Jounce Therapeutics has raised $47.0M across 1 funding round. Most recently, it raised $47.0M Series A in February 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2013 | $47.0M Series A | Deerfield Management |
